Recurrent Refractory Ewing Sarcoma clinical trials

Explore recruiting recurrent refractory ewing sarcoma clinical trials.

Recruiting recurrent refractory ewing sarcoma studies right now

Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Recurrent Refractory Ewing Sarcoma trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A5481092: PHASE 1/2 STUDY TO EVALUATE PALBOCICLIB (IBRANCE®) IN COMBINATION WITH IRINOTECAN AND TEMOZOLOMIDE OR IN COMBINATION WITH TOPOTECAN AND CYCLOPHOSPHAMIDE IN PEDIATRIC PATIENTS WITH RECURRENT OR REFRACTORY SOLID TUMORS

Sweden, France, Czechia, Slovakia, Germany

Phase I and Phase II (Integrated)- Other EU CTIS Study details

Recurrent Refractory Ewing Sarcoma trials by city

Recurrent Refractory Ewing Sarcoma clinical trials

Recruiting recurrent refractory ewing sarcoma studies right now

Study of Onivyde With Talazoparib or Temozolomide in Children With Recurrent Solid Tumors and Ewing Sarcoma

Evaluation of Xaluritamig in Adults, Adolescents and Children With Relapsed or Refractory Ewing Sarcoma (EWS)

Cabozantinib With Ifosfamide in Relapsed/Refractory Sarcomas

Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors

Weekly Irinotecan Liposomes in Recurrent or Refractory Ewing Sarcoma

DFMO Maintenance for Patients With Relapsed/Refractory Ewing Sarcoma or Osteosarcoma

Also recruiting in Europe

A5481092: PHASE 1/2 STUDY TO EVALUATE PALBOCICLIB (IBRANCE®) IN COMBINATION WITH IRINOTECAN AND TEMOZOLOMIDE OR IN COMBINATION WITH TOPOTECAN AND CYCLOPHOSPHAMIDE IN PEDIATRIC PATIENTS WITH RECURRENT OR REFRACTORY SOLID TUMORS

Recurrent Refractory Ewing Sarcoma trials by city

Other conditions